$1,318.00
This Market Spotlight report covers the Thyroid Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, a 10-year disease incidence and five-year prevalence forecast, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Thyroid Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, a 10-year disease incidence and five-year prevalence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways:
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Subtypes
9 TREATMENT
9 Surgery
9 Radioactive iodine (RAI) therapy
9 Thyroid hormone therapy
9 External beam radiation therapy
10 Targeted therapy
11 EPIDEMIOLOGY
15 MARKETED DRUGS
18 PIPELINE DRUGS
22 RECENT EVENTS AND ANALYST OPINION
22 Cabometyx / Cometriq for Thyroid Cancer (September 18, 2021)
23 Cabometyx / Cometriq for Thyroid Cancer (December 21, 2020)
25 KEY REGULATORY EVENTS
25 EMA Recommends New Indication For Ipsen’s Cabometyx
25 Retsevmo Accepted For Use On Scottish NHS On Interim Basis For Thyroid Cancer
25 Exelixis Bids For Cabometyx To Enter Thyroid Cancer Space
27 PROBABILITY OF SUCCESS
28 REVENUE OPPORTUNITY
30 CLINICAL TRIAL LANDSCAPE
31 Sponsors by status
32 Sponsors by phase
34 BIBLIOGRAPHY
35 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of thyroid cancer, 2021–30
18 Figure 2: Overview of pipeline drugs for thyroid cancer in the US
18 Figure 3: Pipeline drugs for thyroid cancer, by company
18 Figure 4: Pipeline drugs for thyroid cancer, by drug type
19 Figure 5: Pipeline drugs for thyroid cancer, by classification
24 Figure 6: Cabometyx / Cometriq for Thyroid Cancer (December 21, 2020): Phase III – COSMIC-311
27 Figure 7: Probability of success in the solid tumors pipeline
30 Figure 8: Clinical trials in thyroid cancer
30 Figure 9: Top 10 drugs for clinical trials in thyroid cancer
31 Figure 10: Top 10 companies for clinical trials in thyroid cancer
31 Figure 11: Trial locations in thyroid cancer
32 Figure 12: Thyroid cancer trials status
33 Figure 13: Thyroid cancer trials sponsors, by phase
LIST OF TABLES
12 Table 1: Incident cases of thyroid cancer, 2021–30
14 Table 2: Five-year prevalent cases of thyroid cancer, 2021–30
16 Table 3: Marketed drugs for thyroid cancer
20 Table 4: Pipeline drugs for thyroid cancer in the US
22 Table 5: Cabometyx / Cometriq for Thyroid Cancer (September 18, 2021)
23 Table 6: Cabometyx / Cometriq for Thyroid Cancer (December 21, 2020)
28 Table 7: Historical global sales, by drug ($m), 2017–21
29 Table 8: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!